Charles River Laboratories International, Inc. CRL
Verdict: Sell. Fair value $170 against a price of $208 on 6 Jan 2026, 18% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: In 2024, Net Income collapsed to $0.01B while Operating Cash Flow remained strong at $0.73B. This.... Net Income fell precipitously from $0.47B in 2023 to just $0.01B in 2024, a drop of 98%, while.... The Accruals Ratio of -0.096 is technically in the 'high quality' range, but this is highly....
Main risks
- Massive Profitability Collapse: Net Income plummeted from $470M in 2023 to just $10M in 2024, crushing Net Margin, ROE, and ROA to near-zero levels.
- Negative Incremental Returns on Capital: The estimated 3-year ROIIC is sharply negative (-27.6%), indicating that capital invested over the last three years has resulted in lower earnings, a severe red flag for capital allocation effectiveness.
- Revenue Stagnation and Decline: After a period of solid growth, revenue has decelerated and turned negative in the most recent year (-1.9% YoY), signaling potential market saturation or competitive pressures.
- In 2024, Net Income collapsed to $0.01B while Operating Cash Flow remained strong at $0.73B. This...
- Net Income fell precipitously from $0.47B in 2023 to just $0.01B in 2024, a drop of 98%, while...
- In 2024, Net Income collapsed to $0.01B while Operating Cash Flow remained strong at $0.73B. This results in an OCF/Net Income ratio of 71.34, indicating that reported GAAP earnings are not at all representative of the company's underlying cash generation. Such a large gap is a major indicator of significant non-cash items distorting the income statement.